WallStSmart

Accenture plc (ACN)vsTenet Healthcare Corporation (THC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Accenture plc generates 236% more annual revenue ($72.11B vs $21.45B). ACN leads profitability with a 10.6% profit margin vs 7.9%. ACN appears more attractively valued with a PEG of 1.27. THC earns a higher WallStSmart Score of 66/100 (B-).

ACN

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 8.0Quality: 5.3
Piotroski: 3/9Altman Z: 2.79

THC

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 6/9Altman Z: 1.69
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ACNUndervalued (+35.7%)

Margin of Safety

+35.7%

Fair Value

$280.38

Current Price

$180.42

$99.96 discount

UndervaluedFair: $280.38Overvalued
THCUndervalued (+78.8%)

Margin of Safety

+78.8%

Fair Value

$1068.55

Current Price

$190.38

$878.17 discount

UndervaluedFair: $1068.55Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACN4 strengths · Avg: 8.5/10
Market CapQuality
$111.04B9/10

Large-cap with strong market position

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

P/E RatioValuation
14.8x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$3.67B8/10

Generating 3.7B in free cash flow

THC4 strengths · Avg: 9.5/10
P/E RatioValuation
10.1x10/10

Attractively priced relative to earnings

Return on EquityProfitability
30.3%10/10

Every $100 of equity generates 30 in profit

EPS GrowthGrowth
87.6%10/10

Earnings expanding 87.6% YoY

Free Cash FlowQuality
$1.46B8/10

Generating 1.5B in free cash flow

Areas to Watch

ACN2 concerns · Avg: 3.5/10
EPS GrowthGrowth
4.0%4/10

4.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

THC4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.8%4/10

2.8% revenue growth

Altman Z-ScoreHealth
1.694/10

Distress zone — elevated risk

Profit MarginProfitability
7.9%3/10

7.9% margin — thin

PEG RatioValuation
4.802/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ACN

The strongest argument for ACN centers on Market Cap, Return on Equity, P/E Ratio. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bull Case : THC

The strongest argument for THC centers on P/E Ratio, Return on Equity, EPS Growth.

Bear Case : ACN

The primary concerns for ACN are EPS Growth, Piotroski F-Score.

Bear Case : THC

The primary concerns for THC are Revenue Growth, Altman Z-Score, Profit Margin.

Key Dynamics to Monitor

THC carries more volatility with a beta of 1.30 — expect wider price swings.

ACN is growing revenue faster at 8.3% — sustainability is the question.

ACN generates stronger free cash flow (3.7B), providing more financial flexibility.

Monitor INFORMATION TECHNOLOGY SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

THC scores higher overall (66/100 vs 62/100). ACN offers better value entry with a 35.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Accenture plc

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Accenture plc is an Irish-domiciled multinational company that provides consulting and processing services. It has been incorporated in Dublin, Ireland since 2009.

Tenet Healthcare Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Tenet Healthcare Corporation is a diversified health services company. The company is headquartered in Dallas, Texas.

Want to dig deeper into these stocks?